Cannabinoid Receptor Antagonists
Products Cannabinoid receptor antagonists are no longer on the market in many countries. Rimonabant (Acomplia) was withdrawn from the market in 2008 because it can cause psychiatric disorders, particularly depression. Effects Cannabinoid receptor antagonists have appetite suppressant, lipid-lowering, antidiabetic, analgesic (antiallodynic, antinociceptive), and anti-inflammatory properties. The effects of cannabinoid receptor antagonists are largely opposite to … Cannabinoid Receptor Antagonists
